Horizon Therapeutics (HZNP) Tops Q3 EPS by 19c; Raises Outlook

Horizon Therapeutics (NASDAQ: HZNP) reported Q3 EPS of $1.25, $0.19 better than the analyst estimate of $1.06. Revenue for the quarter came in at $925.4 million versus the consensus estimate of $893.7 million.

GUIDANCE:

Horizon Therapeutics sees FY2022 revenue of $3.59-3.61 billion, versus the consensus of $3.56 billion.

For earnings history and earnings-related data on Horizon Therapeutics (HZNP) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c